Raymond James raised the firm’s price target on Gilead (GILD) to $103 from $95 and keeps an Outperform rating on the shares. The firm called Gilead’s Q3 earnings beat “solid,” citing strong continued ...

Maxim downgraded Gilead (GILD) to Hold from Buy. The stock has appreciated significantly following a pullback in the first half of the year, ...

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings ...

An ex-Gilead worker who says he was illegally fired for refusing to steal confidential material isn’t protected by a ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...

(Reuters) - Gilead Sciences reported third-quarter financial results that handily beat Wall Street expectations on Wednesday ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...